Literature DB >> 31274776

Matched Retrospective Cohort Study of Thiamine to Treat Persistent Hyperlactatemia in Pediatric Septic Shock.

Scott L Weiss, Bridget Blowey1, Luke Keele2, Rebecca Ganetzky3, Chaya N Murali3, Julie C Fitzgerald4,5, Robert M Sutton4, Robert A Berg4.   

Abstract

OBJECTIVES: Thiamine deficiency may propagate lactate production by limiting pyruvate dehydrogenase activity, and studies suggest benefit for thiamine administration in septic adults. We studied the effect of thiamine on physiologic and clinical outcomes for children with septic shock and hyperlactatemia.
DESIGN: Retrospective matched cohort study.
SETTING: Single academic PICU. PATIENTS: Six thiamine-treated cases and nine matched controls.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was change in blood lactate from prethiamine (T0, cases) or maximum (T0, controls) lactate through 24 hours later (T24). Secondary outcomes were change in lactate over 48 hours (T48) and 72 hours (T72), time to lactate normalization, changes in vasoactive-inotrope score, organ dysfunction severity (daily Pediatric Logistic Organ Dysfunction 2 score), and creatinine, PICU length of stay, and hospital mortality. Lactate was greater than 5 mmol/L for a median of 39 hours (range, 16.1-64.3 hr) prior to thiamine administration for cases compared with 3.4 hours (range, 0-22.9 hr) prior to maximum lactate for controls (p = 0.002). There was no difference in median (interquartile range) change in lactate from T0 to T24 between thiamine-treated cases and controls (-9.0, -17.0 to -5.0 vs -7.2, -9.0 to -5.3 mmol/L, p = 0.78), with both groups exhibiting a rapid decrease in lactate. There were also no differences in secondary outcomes between groups.
CONCLUSIONS: Treatment of pediatric septic shock with thiamine was followed by rapid improvement in physiologic and clinical outcomes after prolonged hyperlactatemia. Although we are not able to infer that thiamine provided benefit over usual care, the rapid decline in lactate after thiamine despite a prolonged period of hyperlactatemia raises the possibility that thiamine helped to reverse lactate production.

Entities:  

Year:  2019        PMID: 31274776      PMCID: PMC6726577          DOI: 10.1097/PCC.0000000000002074

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  19 in total

1.  Thiamine deficiency in critically ill patients with sepsis.

Authors:  Michael W Donnino; Erin Carney; Michael N Cocchi; Ian Barbash; Maureen Chase; Nina Joyce; Peter P Chou; Long Ngo
Journal:  J Crit Care       Date:  2010-06-19       Impact factor: 3.425

2.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuck Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

3.  Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial.

Authors:  Ari Moskowitz; Lars W Andersen; Michael N Cocchi; Mathias Karlsson; Parth V Patel; Michael W Donnino
Journal:  Ann Am Thorac Soc       Date:  2017-05

4.  Low blood thiamine concentrations in children upon admission to the intensive care unit: risk factors and prognostic significance.

Authors:  Lúcio Flávio Peixoto de Lima; Heitor Pons Leite; José Augusto de A C Taddei
Journal:  Am J Clin Nutr       Date:  2010-11-10       Impact factor: 7.045

5.  The American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: Executive Summary.

Authors:  Alan L Davis; Joseph A Carcillo; Rajesh K Aneja; Andreas J Deymann; John C Lin; Trung C Nguyen; Regina S Okhuysen-Cawley; Monica S Relvas; Ranna A Rozenfeld; Peter W Skippen; Bonnie J Stojadinovic; Eric A Williams; Tim S Yeh; Fran Balamuth; Joe Brierley; Allan R de Caen; Ira M Cheifetz; Karen Choong; Edward Conway; Timothy Cornell; Allan Doctor; Marc-Andre Dugas; Jonathan D Feldman; Julie C Fitzgerald; Heidi R Flori; James D Fortenberry; Ana Lia Graciano; Bruce M Greenwald; Mark W Hall; Yong Yun Han; Lynn J Hernan; Jose E Irazuzta; Elizabeth Iselin; Elise W van der Jagt; Howard E Jeffries; Saraswati Kache; Chhavi Katyal; Niranjan Kissoon; Alexander A Kon; Martha C Kutko; Graeme MacLaren; Timothy Maul; Renuka Mehta; Fola Odetola; Kristine Parbuoni; Raina Paul; Mark J Peters; Suchitra Ranjit; Karin E Reuter-Rice; Eduardo J Schnitzler; Halden F Scott; Adalberto Torres; Jacki Weingarten-Abrams; Scott L Weiss; Jerry J Zimmerman; Aaron L Zuckerberg
Journal:  Pediatr Crit Care Med       Date:  2017-09       Impact factor: 3.624

6.  Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.

Authors:  Paul E Marik; Vikramjit Khangoora; Racquel Rivera; Michael H Hooper; John Catravas
Journal:  Chest       Date:  2016-12-06       Impact factor: 9.410

7.  Thiamine, riboflavin, and pyridoxine deficiencies in a population of critically ill children.

Authors:  M Seear; G Lockitch; B Jacobson; G Quigley; A MacNab
Journal:  J Pediatr       Date:  1992-10       Impact factor: 4.406

8.  Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study.

Authors:  Michael W Donnino; Lars W Andersen; Maureen Chase; Katherine M Berg; Mark Tidswell; Tyler Giberson; Richard Wolfe; Ari Moskowitz; Howard Smithline; Long Ngo; Michael N Cocchi
Journal:  Crit Care Med       Date:  2016-02       Impact factor: 7.598

9.  Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass.

Authors:  Michael G Gaies; James G Gurney; Alberta H Yen; Michelle L Napoli; Robert J Gajarski; Richard G Ohye; John R Charpie; Jennifer C Hirsch
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

10.  Fatal metabolic acidosis caused by thiamine deficiency.

Authors:  Moti Klein; Natan Weksler; Gabriel M Gurman
Journal:  J Emerg Med       Date:  2004-04       Impact factor: 1.484

View more
  5 in total

1.  Thiamine in Pediatric Sepsis: A Motivating Study.

Authors:  Halden F Scott
Journal:  Pediatr Crit Care Med       Date:  2019-09       Impact factor: 3.624

Review 2.  Thiamine (vitamin B1) in septic shock: a targeted therapy.

Authors:  Ari Moskowitz; Michael W Donnino
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

Review 3.  Pediatric thiamine deficiency disorders in high-income countries between 2000 and 2020: a clinical reappraisal.

Authors:  Benjamin Rakotoambinina; Laurent Hiffler; Filomena Gomes
Journal:  Ann N Y Acad Sci       Date:  2021-07-26       Impact factor: 6.499

Review 4.  Micronutrient status during paediatric critical illness: A scoping review.

Authors:  L V Marino; F V Valla; R M Beattie; S C A T Verbruggen
Journal:  Clin Nutr       Date:  2020-04-22       Impact factor: 7.324

Review 5.  Vitamin therapy in sepsis.

Authors:  Eric L Wald; Colleen M Badke; Lauren K Hintz; Michael Spewak; L Nelson Sanchez-Pinto
Journal:  Pediatr Res       Date:  2021-07-31       Impact factor: 3.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.